Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

- PMLiVE

Alderley Park ‘will remain flagship bioscience location’

Manchester Science Parks takes over former AstraZeneca site

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

AstraZeneca loses comms head

Neil McCrae to join UK’s Royal Mail

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

- PMLiVE

AZ gets green light for Bydureon pen in US

FDA approval comes after year-long delay

- PMLiVE

Bayer raises sales predictions for new pharma products

Expects Xarelto, Eylea, Stivarga, Xofigo and Adepas to make €7.5bn at peak

Bayer symbol

Bayer buys Chinese consumer care company

Acquires Dihon Pharmaceutical as Algeta takeover closes

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

- PMLiVE

AZ gets limited approval for metreleptin in US

First FDA-backed treatment for rare disease lipodystrophy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links